MarketPeel
Insider Trading Intelligence
AE

Andrea Ellis

BBIO
DIRECTOR · BRIDGEBIO PHARMA, INC. · CIK 0001877680
FILING MIX · LIFETIME58%/42%
BUYS
14
SELLS
10
TOTAL VALUE
$9.43M
COMPANIES
1
ACTIVE SINCE
Aug 2021
HOLDINGS NOW
39,746
AVG SELL PX
$56.49
TRADE KIND
SHOWING 24 / 24
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
5 backtested trades · 8 horizons · 7 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Andrea Ellis, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d5+80.00%+4.84%-1.86%+6.70%+2.77%
14d5+40.00%+7.81%+1.01%+6.80%+7.86%
30d5+40.00%+11.43%+2.14%+9.30%+14.21%
60d5+0.00%+1.35%+4.34%-2.99%-1.12%
90d5+20.00%+12.34%+5.78%+10.09%+18.88%
180d5(1 pending)+25.00%+55.20%+11.83%+43.37%+43.57%
1y5(2 pending)+33.33%+105.51%+12.81%+92.70%+94.80%
2y5(4 pending)+100.00%+221.39%+24.66%+196.72%+196.72%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
BBIO · 39,746 shares · as of Jul 9, 2026
026,23052,46178,691104,92120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 14 buys / 10 sellsCOVERAGE · 21 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
17,167$16.75$287.5K39,746Jul 9, 2026Jul 13, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
17,16717,167Jul 9, 2026Jul 13, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE10b5-1
10b5-1 plan
17,167$84.00$1.44M22,579Jul 9, 2026Jul 13, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
3,99022,579Jun 22, 2026Jun 24, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
5,2775,277Jun 22, 2026Jun 24, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
64,9210Mar 4, 2026Mar 6, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
64,921$8.45$548.6K83,510Mar 4, 2026Mar 6, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE10b5-1
10b5-1 plan
64,921$64.87$4.21M18,589Mar 4, 2026Mar 6, 2026View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE10b5-1
10b5-1 plan
17,167$49.00$841.2K18,589Aug 5, 2025Aug 7, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
17,16734,334Aug 5, 2025Aug 7, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
17,167$16.75$287.5K35,756Aug 5, 2025Aug 7, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
8,4258,425Jun 20, 2025Jun 24, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
6,58918,589Jun 20, 2025Jun 24, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE10b5-1
10b5-1 plan
10,000$35.00$350.0K12,000Apr 14, 2025Apr 16, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
10,00064,921Apr 14, 2025Apr 16, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
10,000$8.45$84.5K22,000Apr 14, 2025Apr 16, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
30,00074,921Apr 1, 2025Apr 3, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE10b5-1
10b5-1 plan
30,000$34.05$1.02M12,000Apr 1, 2025Apr 3, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
30,000$8.45$253.5K42,000Apr 1, 2025Apr 3, 2025View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
26,01426,014Jun 21, 2024Jun 25, 2024View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
51,50151,501Jun 21, 2023Jun 23, 2023View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
104,921104,921Jun 22, 2022Jun 24, 2022View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
12,000$8.39$100.7K12,000Mar 15, 2022Mar 17, 2022View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
49,86949,869Aug 17, 2021Aug 26, 2021View →
Other insiders · BBIO
Loading peer insiders…
About this filer
CIK 0001877680
ROLE
Director
PRIMARY
BBIO
COMPANIES
1
ACTIVE SINCE
Aug 2021
MARKETPEEL · /INSIDER/0001877680DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback